.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,175,018

« Back to Dashboard

Details for Patent: 9,175,018

Title:Boronate ester compounds and pharmaceutical compositions thereof
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Elliott; Eric L. (Brighton, MA), Ferdous; Abu J. (Winchester, MA), Kaufman; Michael J. (Lexington, MA), Komar; Sonja A. (Belmont, MA), Mazaik; Debra L. (Holliston, MA), Mccubbin; Quentin J. (Belmont, MA), Nguyen; Phuong M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Skwierczynski; Raymond D. (Andover, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Newton, MA), Zawaneh; Peter N. (Cambridge, MA)
Assignee:
Filing Date:Aug 01, 2014
Application Number:14/449,328
Claims:1. A process for generating a compound of Formula (II) ##STR00018## or a pharmaceutically acceptable salt thereof, wherein A is 0, 1, or 2; P is R.sup.c--C(O)--; R.sup.c is R.sup.D; R.sup.D is substituted or unsubstituted mono- or bicyclic ring system selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, naphthyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and dihydrobenzoxazinyl; R.sup.a is hydrogen, C.sub.1-6 aliphatic, C.sub.1-6 fluoroaliphatic, --(CH.sub.2).sub.m--CH.sub.2--R.sup.B, --(CH.sub.2).sub.m--CH.sub.2--NHC(.dbd.NR.sup.4)NH--Y, --(CH.sub.2).sub.m--CH.sub.2--CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH.sub.2--N(R.sup.4)CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.6)N(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.5a)--OR.sup.5b, or --(CH.sub.2).sub.m--CH(R.sup.5)--SR.sup.5; R.sup.a1 is hydrogen, C.sub.1-6 aliphatic, C.sub.1-6 fluoroaliphatic, --(CH.sub.2).sub.m--CH.sub.2--R.sup.B, --(CH.sub.2).sub.m--CH.sub.2--NHC(.dbd.NR.sup.4)NH--Y, --(CH.sub.2).sub.m--CH.sub.2--CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH.sub.2--N(R.sup.4)CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.6)N(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.5a)--OR.sup.5b, or --(CH.sub.2).sub.m--CH(R.sup.5)--SR.sup.5; each R.sup.a2 independently is hydrogen, C.sub.1-6 aliphatic, C.sub.1-6 fluoroaliphatic, --(CH.sub.2).sub.m--CH.sub.2--R.sup.B, --(CH.sub.2).sub.m--CH.sub.2--NHC(.dbd.NR.sup.4)NH--Y, --(CH.sub.2).sub.m--CH.sub.2--CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH.sub.2--N(R.sup.4)CON(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.6)N(R.sup.4).sub.2, --(CH.sub.2).sub.m--CH(R.sup.5a)--OR.sup.5b, or --(CH.sub.2).sub.m--CH(R.sup.5)--SR.sup.5; each R.sup.B independently is a substituted or unsubstituted mono- or bicyclic ring system; each R.sup.4 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R.sup.4 on the same nitrogen atom, taken together with the nitrogen atom, form a substituted or unsubstituted 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms independently selected from N, O, and S; each R.sup.5 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; each R.sup.5a independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; each R.sup.5b independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; each R.sup.6 independently is a substituted or unsubstituted aliphatic, aryl, or heteroaryl group; Y is hydrogen, --CN, or --NO.sub.2; m is 0, 1, or 2; each of R.sup.b1 and R.sup.b2 independently is hydrogen, --CO.sub.2H, --OH, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; each of R.sup.b3 and R.sup.b4 independently is hydrogen, --CO.sub.2H, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or R.sup.b2 and R.sup.b4 are each independently hydrogen, and R.sup.b1 and R.sup.b3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S; or R.sup.b2 and R.sup.b4 are absent, and R.sup.b1 and R.sup.b3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S; and n is 0 or 1; the process comprising: (1a) coupling a compound of Formula (vi) with a compound, P-LG, to form a compound of Formula (vii) ##STR00019## wherein PG is hydrogen or a protecting group; and LG is a leaving group; (2a) deprotecting the compound of Formula (vii) to form a compound of Formula (viia) ##STR00020## (3a) coupling the compound of Formula (viia) with a compound of Formula (i) to form a compound of Formula (iv) ##STR00021## wherein X.sup.- is a counter anion; (4) deprotecting the compound of Formula (iv) to form a compound of Formula (v) ##STR00022## and (5) reacting the compound of Formula (v) with an alpha hydroxy carboxylic acid or a beta hydroxy carboxylic acid to form a compound of Formula (II).

2. The process of claim 1, wherein the reaction of step (1a) or step (3a) or both is conducted in the presence of a peptide coupling reagent.

3. The process of claim 2, wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent, phosphonium reagent, and uronium reagent.

4. The process of claim 3, wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), and O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU).

5. The process of claim 1, further comprising converting the carboxylic acid moiety of compound (viia) to an activated ester or acid halide prior to the reaction of step (3a).

6. The process of claim 5, wherein said activated ester or acid halide is an O--(N-hydroxysuccinnimide) ester.

7. The process of claim 1, wherein the reaction of step (1a) is conducted in the presence of a solvent.

8. The process of claim 7, wherein the solvent is tetrahydrofuran.

9. The process of claim 1, wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.

10. The process of claim 9, wherein the mineral acid is hydrochloric acid.

11. The process of claim 1, wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.

12. The process of claim 11, wherein the organic boronic acid acceptor is i-BuB(OH).sub.2.

13. The process of claim 1, wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl acetate, methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dioxane, dichloromethane, toluene, heptane, methyl-cyclohexane, tert-butylmethyl ether, and any combination thereof.

14. The process of claim 1, wherein the reaction of step (5) is conducted in the presence of a catalyst, wherein the catalyst is an organic amine base.

15. The process of claim 14, wherein the catalyst is selected from the group consisting of triethylamine, triethylenediamine, pyridine, collidine, 2,6-lutidine, 4-dimethylaminopyridine, di-tertbutylpyridine, N-methylmorpholine, N-methylpiperidine, tetramethylguanidine, diazabicyclo[5.4.0]undec-7-ene (DBU), 1,4-diazabicyclo[2.2.2]octane, 1,5-diazabicycle[4.3.0]non-5-ene, N,N'diisopropylethylamine, or any combination thereof.

16. The process of claim 1, wherein step (5) further comprises cooling the solution.

17. The process of claim 16, wherein the cooling comprises cooling the solution uncontrolled until the internal temperature is about 25.degree. C.

18. The process of claim 16, wherein the cooling is conducted in the presence of a co-solvent.

19. The process of claim 18, wherein the co-solvent is selected from the group consisting of heptane, methylcyclohexane, toluene, tert-butylmethyl ether, ethyl acetate, or any combination thereof.

20. The process of claim 1, further comprising (6) isolating the compound of Formula (II) as a crystalline solid.

21. The process of claim 1, wherein PG is a protecting group selected from the group consisting of an acyl protecting group and a urethane protecting group.

22. The process of claim 21, wherein PG is a protecting group selected from the group consisting of formyl, acetyl, succinyl, methoxysuccinyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and fluorenylmethoxycarbonyl (Fmoc).

23. The process of claim 1, wherein LG is --Cl.

24. The process of claim 1, wherein X.sup.- is CF.sub.3CO.sub.2.sup.-.

25. The process of claim 1, wherein R.sup.c is selected from the group consisting of 2,5-dichlorophenyl.

26. The process of claim 1, wherein A is 0; R.sup.a is C.sub.1-6 aliphatic; R.sup.a1 is hydrogen, C.sub.1-6 aliphatic, --(CH.sub.2).sub.m--CH.sub.2--R.sup.B, or --(CH.sub.2).sub.m--CH(R.sup.5a)--OR.sup.5b; each of R.sup.b1 and R.sup.b2 independently is hydrogen, --CO.sub.2H, --OH, or a substituted or unsubstituted aliphatic; each of R.sup.b3 and R.sup.b4 independently is hydrogen, C.sub.1-6 aliphatic, or --(CH.sub.2).sub.pCO.sub.2H; and p is 0 or 1.

27. The process of claim 1, wherein A is 0; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; R.sup.a1 is hydrogen; each R.sup.b1 and R.sup.b2 independently is hydrogen; each R.sup.b3 and R.sup.b4 independently is --(CH.sub.2).sub.p--CO.sub.2H; p is 0 or 1; and n is 0 or 1.

28. The process of claim 1, wherein the alpha hydroxy carboxylic acid or a beta hydroxy carboxylic acid is citric acid.

29. The process of claim 1, wherein the compound of Formula (II) is 4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-m- ethylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid.

30. The process of claim 1, wherein the compound of Formula (II) is 2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid.

31. A process for generating a compound, Form-1, ##STR00023## the process comprising the steps of (1) reacting a compound, int-1, with glycine to form a compound, int-2 ##STR00024## (2) reacting the compound, int-2, with a compound, int-3, to form a compound, int-4 ##STR00025## (3) reacting the compound, int-4, with HCl to form a compound, int-5 ##STR00026## (4) reacting the compound, int-5, with citric acid to form the compound, Form-1 ##STR00027##

32. The process of claim 31, wherein the reaction of step (1) is conducted in the presence of NaOH.

33. The process of claim 31, wherein the reaction of step (2) is conducted in the presence of TBTU.

34. The process of claim 31, wherein the reaction of step (2) is conducted in the presence of DIPEA.

35. The process of claim 31, wherein the reaction of step (3) is conducted in the presence of methanol and hexane.

36. The process of claim 31, wherein the reaction of step (4) is conducted in the presence of ethyl acetate.

37. The process of claim 31, wherein the reaction of step (4) comprises cooling the solution uncontrolled until the internal temperature is about 25.degree. C.

38. A process for generating a compound, Form-1, ##STR00028## the process comprising reacting a compound, int-5, with citric acid to form the compound, Form-1 ##STR00029##

39. The process of claim 38, wherein the reaction is conducted in the presence of ethyl acetate.

40. The process of claim 38, wherein the reaction further comprises cooling the solution uncontrolled until the internal temperature is about 25.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc